597 related articles for article (PubMed ID: 9713486)
21. [Mechanisms of drug resistance of two cell lines of human chronic promyelocytic leukemia K562, resistant to DNA topoisomerase II inhibitors adriamycin and etoposide].
Meliksetian MB; Berezkina EV; Pavlenko MA; Grinchuk TM
Tsitologiia; 1999; 41(7):615-21. PubMed ID: 10496023
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
23. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
24. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines.
Brown GA; McPherson JP; Gu L; Hedley DW; Toso R; Deuchars KL; Freedman MH; Goldenberg GJ
Cancer Res; 1995 Jan; 55(1):78-82. PubMed ID: 7805045
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
[TBL] [Abstract][Full Text] [Related]
26. The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes.
Ferraro C; Quemeneur L; Fournel S; Prigent AF; Revillard JP; Bonnefoy-Berard N
Cell Death Differ; 2000 Feb; 7(2):197-206. PubMed ID: 10713734
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
28. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
29. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
30. Apoptosis of androgen-independent mammary and prostate cell lines induced by topoisomerase inhibitors: common pathway of gene regulation.
Furuya Y; Ohta S; Ito H
Anticancer Res; 1997; 17(3C):2089-93. PubMed ID: 9216669
[TBL] [Abstract][Full Text] [Related]
31. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines.
Schmidt F; Knobbe CB; Frank B; Wolburg H; Weller M
Oncol Rep; 2008 Apr; 19(4):1061-6. PubMed ID: 18357397
[TBL] [Abstract][Full Text] [Related]
32. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines.
Beidler DR; Chang JY; Zhou BS; Cheng YC
Cancer Res; 1996 Jan; 56(2):345-53. PubMed ID: 8542590
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
34. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
[TBL] [Abstract][Full Text] [Related]
35. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
[TBL] [Abstract][Full Text] [Related]
36. Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities.
Schmitt E; Cimoli G; Steyaert A; Bertrand R
Exp Cell Res; 1998 Apr; 240(1):107-21. PubMed ID: 9570926
[TBL] [Abstract][Full Text] [Related]
37. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
[TBL] [Abstract][Full Text] [Related]
38. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
39. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
Fujimori A; Gupta M; Hoki Y; Pommier Y
Mol Pharmacol; 1996 Dec; 50(6):1472-8. PubMed ID: 8967967
[TBL] [Abstract][Full Text] [Related]
40. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
